Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. Kirkpatrick BD, et al. Among authors: larsson cj. Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16. Sci Transl Med. 2016. PMID: 27089205 Clinical Trial.
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. Durbin AP, et al. Among authors: larsson cj. J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17. J Infect Dis. 2013. PMID: 23329850 Free PMC article. Clinical Trial.
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. Kirkpatrick BD, et al. Among authors: larsson cj. J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22. J Infect Dis. 2015. PMID: 25801652 Free PMC article. Clinical Trial.
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. Durbin AP, et al. Among authors: larsson cj. J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16. J Infect Dis. 2016. PMID: 26908742 Free PMC article. Clinical Trial.
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD. Whitehead SS, et al. Among authors: larsson cj. PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584. doi: 10.1371/journal.pntd.0005584. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28481883 Free PMC article. Clinical Trial.
In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.
Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD. Lyon CE, et al. Among authors: larsson cj. Vaccine. 2010 Apr 30;28(20):3602-8. doi: 10.1016/j.vaccine.2010.02.017. Epub 2010 Feb 24. Vaccine. 2010. PMID: 20188175 Clinical Trial.
Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.
Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Fingar A, Poly F, Fimlaid KA, Hoq F, Tribble DR. Kirkpatrick BD, et al. Among authors: larsson cj. Clin Infect Dis. 2013 Oct;57(8):1106-13. doi: 10.1093/cid/cit454. Epub 2013 Jul 9. Clin Infect Dis. 2013. PMID: 23840001 Free PMC article. Clinical Trial.
Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.
Baqar S, Tribble DR, Carmolli M, Sadigh K, Poly F, Porter C, Larsson CJ, Pierce KK, Guerry P; Campylobacter Study Team; Darsley M, Kirkpatrick B. Baqar S, et al. Among authors: larsson cj. Clin Vaccine Immunol. 2010 Jan;17(1):80-6. doi: 10.1128/CVI.00252-09. Epub 2009 Nov 18. Clin Vaccine Immunol. 2010. PMID: 19923572 Free PMC article.
Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09).
Kirkpatrick BD, Bentley MD, Thern AM, Larsson CJ, Ventrone C, Sreenivasan MV, Bourgeois L. Kirkpatrick BD, et al. Among authors: larsson cj. Clin Diagn Lab Immunol. 2005 Sep;12(9):1127-9. doi: 10.1128/CDLI.12.9.1127-1129.2005. Clin Diagn Lab Immunol. 2005. PMID: 16148184 Free PMC article. Clinical Trial.
16 results